GoodRx (NASDAQ:GDRX) Sets New 1-Year Low – What’s Next?
by Doug Wharley · The Cerbat GemGoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.61 and last traded at $2.6250, with a volume of 784068 shares. The stock had previously closed at $2.68.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on GDRX shares. UBS Group restated a “reduce” rating on shares of GoodRx in a research note on Monday, January 5th. Wall Street Zen upgraded shares of GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup decreased their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. JPMorgan Chase & Co. cut their target price on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Finally, TD Cowen decreased their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, GoodRx presently has an average rating of “Hold” and a consensus price target of $4.91.
Check Out Our Latest Analysis on GDRX
GoodRx Price Performance
The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s 50-day moving average price is $2.78 and its 200-day moving average price is $3.72. The company has a market capitalization of $882.52 million, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 1.02 and a beta of 1.45.
GoodRx (NASDAQ:GDRX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. During the same quarter last year, the firm earned $0.08 EPS. The business’s revenue for the quarter was up .4% on a year-over-year basis. Equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.
Hedge Funds Weigh In On GoodRx
Hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in GoodRx in the third quarter worth about $33,000. Boothbay Fund Management LLC acquired a new stake in shares of GoodRx during the 3rd quarter worth approximately $43,000. Shay Capital LLC acquired a new stake in shares of GoodRx during the 3rd quarter worth approximately $47,000. Cetera Investment Advisers bought a new stake in shares of GoodRx during the second quarter worth approximately $50,000. Finally, Walled Lake Planning & Wealth Management LLC acquired a new position in GoodRx in the second quarter valued at approximately $55,000. Institutional investors own 63.77% of the company’s stock.
About GoodRx
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.